Our key Figures
 | 22,000 employeesin 66 countries, including 5,000 in France. |
 | 98% of Servier medicinesactive ingredients are synthesized in its own plant in Bolbec-Baclair in France. |
 | 100 million patientstreated each day worldwide with Servier medicines. |
 | 5 major R&D areascardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes. |
 | 30 drug candidatesin clinical development, including 16 new molecular entities. |
 | A strong international presence95% of revenue from brand-name medicines. |
| | 16 chemical and pharmaceutical production sites |
 | 15 International Centers for Therapeutic Researchand 3 research institutes (2 in France and 1 in Hungary). |
 | €4,615 billion euros in revenuecomprising €3.2 billion for brand-name medicines and €1.4 billion for generic medicines. |
 | 25 % of revenue from brand-name medicines invested in R&Deach year on average, excluding generics. |
 | No. 1 independent French pharmaceutical company33rd largest pharmaceutical company worldwide. |
 | A leader position in cardiology in Franceno. 2 in Europe, No. 6 in the world [1]. |
 | Participation reached 23,2% of the trade balance surplus in FranceIn pharmaceuticals and fine chemicals (brand-name medicines), amounting to €1.5 billion. |
Our key figures as of September 30th, 2019
[1] Source: IQVA, Analytics Link – MAT Q3-2019: 74 countries.